What is the optimal management strategy for a patient with heart failure with reduced ejection fraction (HFrEF) and impaired functional status?

Optimal Management of Heart Failure with Reduced Ejection Fraction and Impaired Functional Status

Immediate Initiation of Quadruple Therapy

All patients with HFrEF and impaired functional status (NYHA Class II-IV) should immediately start four foundational medication classes simultaneously: an SGLT2 inhibitor, a mineralocorticoid receptor antagonist (MRA), a beta-blocker, and an ARNI (or ACE inhibitor/ARB if ARNI not tolerated), along with loop diuretics for volume management. 1, 2, 3 This quadruple therapy provides approximately 5.3 additional life-years compared to no treatment, with the combination reducing all-cause mortality by 61% (HR 0.39,95% CI: 0.32-0.49). 4

Sequencing Strategy for Medication Initiation

Start medications in this specific order to maximize tolerability and adherence:

• First: Initiate SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) and MRA (spironolactone 25 mg daily) simultaneously, as both have minimal blood pressure effects. 2, 3 SGLT2 inhibitors cause only -1.50 mmHg average BP decrease in patients with baseline SBP 95-110 mmHg, diminishing to <1 mmHg after 4 months. 2

• Second (1-2 weeks later): Add low-dose beta-blocker (carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily) if heart rate >70 bpm. 2, 3

• Third (1-2 weeks later): Initiate ARNI (sacubitril/valsartan 24/26 mg twice daily, or 49/51 mg twice daily if previously on ACE inhibitor) or ACE inhibitor (enalapril 2.5 mg twice daily) if ARNI not tolerated. 2, 3

• Loop diuretics: Adjust dose daily based on symptoms and weight (furosemide 20-40 mg once or twice daily, torsemide 10-20 mg once daily, or bumetanide 0.5-1.0 mg once or twice daily). 2

Aggressive Uptitration Protocol

Uptitrate one drug at a time every 1-2 weeks using small increments until target doses are achieved: 2, 3

• Carvedilol: 3.125 mg → 6.25 mg → 12.5 mg → 25 mg twice daily (target: 25-50 mg twice daily) 3
• Metoprolol succinate: 12.5-25 mg → 50 mg → 100 mg → 200 mg daily (target) 3
• Bisoprolol: 1.25 mg → 2.5 mg → 5 mg → 10 mg daily (target) 3
• Sacubitril/valsartan: 24/26 mg → 49/51 mg → 97/103 mg twice daily (target) 3
• Spironolactone: 25 mg daily → 50 mg daily (if tolerated at 8 weeks) 5

The evidence-based beta-blockers (carvedilol, metoprolol succinate, bisoprolol) reduce mortality by at least 20% and decrease sudden cardiac death. 2 ARNI provides at least 20% mortality reduction superior to ACE inhibitors. 2

Managing Low Blood Pressure During Optimization

Never discontinue or reduce GDMT for asymptomatic hypotension with adequate perfusion. 6, 2 GDMT medications maintain efficacy and safety even in patients with baseline SBP <110 mmHg. 6, 2

Algorithm for Symptomatic Hypotension (SBP <80 mmHg or major symptoms):

Step 1: Address reversible non-HF causes first: 6, 2

• Stop alpha-blockers (tamsulosin, doxazosin, terazosin, alfuzosin)
• Discontinue other non-essential BP-lowering medications
• Evaluate for dehydration, infection, or acute illness
• Consider spacing out medication administration times

Step 2: Non-pharmacological interventions: 6

• Compression leg stockings for orthostatic symptoms
• Exercise and physical training programs
• Adequate salt and fluid intake if not volume overloaded

Step 3: If symptoms persist after addressing Steps 1-2, reduce GDMT in this specific order: 6

• If heart rate >70 bpm: Reduce ACEi/ARB/ARNI dose first
• If heart rate <60 bpm: Reduce beta-blocker dose first
• Always maintain: SGLT2 inhibitor and MRA (minimal BP effects)

Critical caveat: Discontinuing RAASi after hypotension is associated with two to fourfold higher risk of subsequent adverse events compared to continuing therapy. 6

Monitoring Requirements

Check at 1-2 weeks after each dose increment: 2, 3

• Blood pressure and heart rate
• Serum creatinine and eGFR (modest increases up to 30% above baseline are acceptable and should not prompt discontinuation) 2
• Serum potassium (target <5.0 mEq/L before initiating MRA; use potassium binders like patiromer if hyperkalemia develops rather than stopping MRA) 2, 5

Baseline laboratory assessment should include: complete blood count, urinalysis, fasting lipids, liver function, electrolytes, BUN, creatinine, glucose, and TSH. 3

Device Therapy Considerations

Implantable Cardioverter-Defibrillator (ICD): Indicated for patients with LVEF ≤35% and NYHA Class II-III symptoms despite ≥3 months of optimal medical therapy, who are expected to survive >1 year with good functional status. 2 This applies to both ischemic cardiomyopathy (primary prevention) and those who have recovered from ventricular arrhythmia causing hemodynamic instability (secondary prevention). 2

Cardiac Resynchronization Therapy (CRT): Recommended for symptomatic HFrEF patients in sinus rhythm with QRS duration ≥150 msec and left bundle branch block (LBBB) morphology with LVEF ≤35% despite optimal medical therapy. 2 CRT improves clinical outcomes and functional status. 3

Additional Therapies for Persistent Symptoms

Vericiguat: For high-risk patients with worsening HFrEF despite quadruple therapy, vericiguat (starting 2.5 mg daily, target 10 mg daily) may provide an additional 0.7 life-years beyond quadruple therapy. 4 This represents quintuple therapy with a combined HR for all-cause mortality of 0.35 (95% CI: 0.27-0.45). 4

Ivabradine: Consider if heart rate ≥70 bpm in sinus rhythm despite maximally tolerated beta-blocker (starting dose 2.5-5 mg twice daily). 2 However, survival benefit is modest or negligible in the broad HFrEF population. 2

Hydralazine/isosorbide dinitrate: Indicated for self-identified Black patients with NYHA class III-IV symptoms despite optimal therapy (starting dose: hydralazine 25 mg three times daily + isosorbide dinitrate 20 mg three times daily). 2 Can also be used in patients intolerant to ACE inhibitors/ARBs/ARNI, though it may be inferior to ACE inhibitors for mortality. 2

Volume Management Strategy

Titrate loop diuretic dose to achieve euvolemia (no peripheral edema, no orthopnea, no jugular venous distension), then use the lowest dose that maintains this state. 2 Loop diuretics are essential for congestion control but do not reduce mortality. 2

Physical examination findings indicating volume status: 2

• Congestion: Peripheral edema, jugular venous distension, pulmonary rales, hepatomegaly
• Poor perfusion: Cool extremities, narrow pulse pressure, altered mental status

Important caveat: Signs may be absent in early HF or in patients already treated with diuretics. 2

Critical Medications to Avoid

• Diltiazem or verapamil: Increase risk of worsening heart failure and hospitalization 2
• Triple combination of ACE inhibitor + ARB + MRA: Increased risk of renal dysfunction and hyperkalemia 2
• ACE inhibitor combined with ARNI: Risk of angioedema 2
• NSAIDs: Interfere with ACE inhibitor efficacy and worsen renal function 3
• Non-evidence-based beta-blockers: Use only carvedilol, metoprolol succinate, or bisoprolol 2, 3

Common Pitfalls to Avoid

1. Delaying initiation of all four medication classes simultaneously - start all together, not sequentially over months 2, 3
2. Accepting suboptimal doses - only 1% of eligible patients achieve target doses of all recommended drugs in real-world practice 2, 3
3. Stopping medications for asymptomatic hypotension - adverse events occur in 75-85% of HFrEF patients regardless of treatment, with no substantial difference between GDMT and placebo arms 2
4. Inadequate monitoring - early follow-up within 1-2 weeks of medication changes is associated with improved outcomes 3
5. Using thiazides if GFR <30 mL/min unless combined synergistically with loop diuretics 3
6. Excessive diuresis before starting ACE inhibitors - can precipitate hypotension 3

Referral Criteria for Advanced Heart Failure

Refer to HF specialist when: 3

• Persistent low blood pressure with major symptoms despite optimization attempts
• Inability to uptitrate GDMT due to hemodynamic intolerance
• Refractory symptoms on optimal medical therapy
• Consideration for mechanical circulatory support or transplantation evaluation 1